Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 27450106.
- Also identified by DOI 10.1016/j.eururo.2016.07.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.
Medical subject headings
- Androgen Antagonists
- Hyperglycemia
- Hypoglycemic Agents
- Metformin
- Orchiectomy
- Prostatic Neoplasms